$5.72
Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Seres Therapeutics Files $300 Million Mixed Shelf
Seres Therapeutics: Q2 Earnings Snapshot
Overview
52-week range
$4.32
$30
5% of range
Avg surprise (last 2)
-108.9%
Avg reaction (last 2)
-2.8%
0% positive
Latest IV / EM
168%
EM ±26.2% · $5 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.47 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-2.08 | — | — | +7.1% | -2.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.94 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-2.27 | $-2.72 | +16.5% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-2.24 | $-0.67 | -234.3% | — | -3.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $11.63 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-4.34 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-5.49 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.37 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.36 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.57 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $736,000 | $358,000 | — | $351,000 | $0 | $0 | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-21M | $-21M | — | $-22M | $-25M | $-27M | — | $-29M |
| Net income | $5M | $-20M | — | $8M | $-20M | $33M | — | $89M |
| EPS (diluted) | $0.47 | $-2.08 | — | $0.94 | $-2.27 | $3.75 | — | $11.63 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16M | $30M | $46M | $48M | $45M | $59M | $31M | $67M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $42M | $32M | $49M | $52M | $49M | $66M | $39M | $73M |
| Total assets | $102M | $118M | $138M | $143M | $144M | $164M | $140M | $179M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $67M | $91M | $94M | $100M | $111M | $114M | $126M | $155M |
| Total equity | $35M | $26M | $44M | $44M | $33M | $50M | $14M | $24M |